Drug Trial Radar · NCT04809142
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
Last checked: Nov 19, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
392
Planned (sponsor's estimate)
Start
Feb 4, 2021
Primary completion
Mar 18, 2022
Study completion Feb 1, 2023
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced biliary cancer.
Conditions
- Advanced Biliary Cancer
Interventions
TQB2450 InjectionDrug
TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Anlotinib hydrochlorideDrug
Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Oxaliplatin injectionDrug
Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
Capecitabine tabletsDrug
Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
Gemcitabine hydrochloride injectionDrug
Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: up to 40 weeks
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincal Hospital
Hefei, Anhui, China · Not yet recruiting
Beijing Chao-Yang Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Youan Hospital,Captical Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
Affiliated Hospital of Hebei University
Baoding, Hebei, China · Not yet recruiting
Cangzhou Central Hospital
Cangzhou, Hebei, China · Not yet recruiting
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China · Not yet recruiting
Harbin Medical University Affiliated Tumor Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Tumor Hospital
Zhengzhou, Henan, China · Not yet recruiting
Tongji Medical College of HUST
Wuhan, Hubei, China · Not yet recruiting
Hunan Provincial People's Hospital
Changsha, Hunan, China · Not yet recruiting
The First Peoples Hospital of Changzhou
Changzhou, Jiangsu, China · Not yet recruiting
The First Bethune Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.